Company intelligence / Profile preview

Synchronicity Group

San Jose, California, United Statessynchronicitygroup.com ↗

Ownership: Private
Development stage: Other

Overview

Synchronicity Pharma has developed the first clinical-stage compound shown to safely target core-clock molecular machinery and modulate clock-regulated gene expression in humans. Its lead molecule, SHP1705, is a cryptochrome stabilizer that has demonstrated safety and active core clock control in early clinical testing. Phase II trials are planned for glioblastoma patients within two to three years. Other molecules are being studied for colorectal cancer, liver cancer, acute myeloid leukemia, and sleep-wake disorders. Preclinical data show reduced proliferation of glioblastoma stem cells by targeting circadian proteins.

Therapeutic areas: OncologyPsychiatryHematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

SP1002

Preclinical

Beyond the preview

Go deeper on Synchronicity Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synchronicity Group.

Explore the full profile